1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 24 NOVEMBER 2014

Cancer Drug News 24 NOVEMBER 2014

  • November 2014
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - BMS/Merck Battle For Melanoma Market Share
Industry Brief - Revlimid Gains Swissmedic Approval For r/r MCL
Industry Brief - Teva Launches Liquid Formulation Of Treanda Injection In US
Industry Brief - BerGenBio's BGB324 Gains FDA ODD For AML
Industry Trend Analysis - GSK Collaboration Boosts Clovis In Race For Third-Generation NSCLC Drug
Industry Trend Analysis - PCA Vaccines Still Have A Future Despite Disappointing Provenge Sales
Industry Brief - Merrimack's MM-398 Gains FDA Fast Track Designation For Post-Gemcitabine MPC
Industry Brief - NW Bio Raises Funds To Expand/Accelerate DCVax-L And DCVax-Direct Programmes
Industry Brief - Mekinist+Tafinlar Combination Significantly Improved OS In COMBI-v Study
Industry Brief - Provectus/Sinopharm Extend MoU
Industry Brief - 3SBio/PharmAbcine Sign Tanibirumab Licensing Deal
Industry Brief - Beactica Awarded Funding To Develop Epigenetic Cancer Drugs
Industry Brief - TapImmune/VGTI Florida Collaborate To Develop Breast/Ovarian Cancer Vaccines

Table Of Contents

Cancer Drug News 24 NOVEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in Australia - Forecast

  • February 2017
    4 pages
  • Cancer  

    Ovarian Cancer  

  • Australia  

    Oceania  

View report >

Cancer Statistics in the UK

  • February 2017
    11 pages
  • Cancer  

  • United Kingdom  

    Australia  

    Denmark  

View report >

Cancer Statistics in the UK

  • February 2017
    18 pages
  • Cancer  

  • United Kingdom  

View report >

Cancer Statistics

7 days ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.